Сравнительное проспективное мультидисциплинарное исследование эффективности холина альфосцерата в профилактике прогрессирования когнитивного дефицита у родственников пациентов с болезнью Альцгеймера

The objective : of the study was to perform the comparative evaluation of three-year observation of cognitive dysfunction indices dynamics during conducting repeated courses of preventive treatment with choline alfoscerate (Cereton), which was assigned to first-degree relatives of patients with Alzheimer’s disease (AD). Materials and methods : first-degree relatives of patients with Alzheimer’s disease were included in the study. Changes in cognitive functioning indices were compared between the group, consisting of 30 relatives (9 subjects with mild cognitive impairment syndrome and 21 participants with signs of cognitive impairment), who had received three courses of 3-months therapy with choline alfoscerate (Cereton) at a daily dose of 1200 mg for three years, and the group, including 32 relatives, who had not received treatment with drugs. Methods . Clinical-psychological, psychometric, molecular-genetic, neurointrascopic, and statistical methods were used. Results : transition from mild cognitive impairment (MCI) syndrome was established in 28.7% of cases in therapeutic group. Significant reduction in cognitive dysfunction within the framework of MCI syndrome, as well as a decrease in cognitive dysfunction intensity were noticed in 66.7% of cases. Positive effect of treatment, assessed according to CGI (Clinical Global Impression scale) was established in 56.7% of relatives, included in the study. Statistically significant improvement of MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) indices, as well as indices of tests, differentially assessing various components of cognitive functioning, was achieved in therapeutic group, while in the group of relatives, who had not received drug treatment, significant worsening of cognitive functioning indices was revealed. Conclusion : the results of preventive course treatment with choline alfoscerate showed positive effect of the drug on the cognitive status of close relatives of patients with AD up to transition of the syndrome of mild cognitive impairment.